Multiaptamer target detection
Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions.
1. A composition comprising a first aptamer, second aptamer, and a target,
wherein the first aptamer comprises a first C-5 pyrimidine modification scheme, the second aptamer comprises a second C-5 pyrimidine modification scheme, and wherein the first C-5 pyrimidine modification scheme and the second C-5 pyrimidine modification scheme are different;
wherein the first C-5 pyrimidine modification scheme comprises a 5-(N-benzylcarboxyamide)-2′-deoxyuridine (BndU); and
wherein the first aptamer, second aptamer and the target are capable of forming a ternary complex.
2. The composition of claim 1 , wherein the first aptamer has binding affinity for the target and not the second aptamer.
3. The composition of claim 1 , wherein the second aptamer has binding affinity for the target and not the first aptamer.
4. The composition of claim 1 , wherein the second aptamer has binding affinity for a complex formed by the association of the first aptamer with the target.
5. The composition of claim 1 , wherein the first aptamer binding region of the target and the second aptamer binding region of the target are different regions.
6. The composition of claim 1 , wherein the first aptamer and the second aptamer, independently, comprise RNA, DNA or a combination thereof.
7. The composition of claim 1 , wherein percent GC content of the first aptamer and second aptamer are, independently, from about 37% to about 58%.
8. The composition of claim 1 , wherein the first aptamer comprises from about 9 to about 16 C-5 modified pyrimidines.
9. The composition of claim 1 , wherein each uracil or thymine of the first aptamer is a 5-(N-benzylcarboxyamide)-2′-deoxyuridine (BndU).
10. The composition of claim 1 , wherein the second aptamer comprises from about 5 to about 15 C-5 modified pyrimidines.
11. The composition of claim 1 , wherein the second C-5 pyrimidine modification scheme comprises a C-5 modified pyrimidine selected from the group consisting of 5-(N-tryptaminocarboxyamide)-2′-deoxyuridine (TrpdU), 5-[N-(1-naphthylmethyl)carboxyamide]-2′-deoxyuridine (NapdU), 5-[N-(2-naphthylmethyl)carboxyamide]-2′-deoxyuridine (2-NapdU), and a combination thereof.
12. The composition of claim 1 , wherein each uracil or thymine of the second aptamer is a C-5 modified pyrimidine selected from the group consisting of 5-(N-tryptaminocarboxyamide)-2′-deoxyuridine (TrpdU), 5-[N-(1-naphthylmethyl)carboxyamide]-2′-deoxyuridine (NapdU), and 5-[N-(2-naphthylmethyl)carboxyamide]-2′-deoxyuridine (2-NapdU).
13. The composition of claim 1 , wherein the first aptamer and the second aptamer, independently, are each from 20 to 100 nucleotides in length.
14. The composition of claim 1 , wherein the first aptamer and/or the second aptamer further comprise a detectable moiety.
15. The composition of claim 14 , wherein the detectable moiety is selected from the group consisting of a dye, a quantum dot, a radiolabel, an electrochemical functional group, an enzyme, an enzyme substrate, a ligand and a receptor.
16. The composition of claim 1 , wherein the target comprises a protein or a peptide.
17. The composition of claim 16 , wherein the target is a protein selected from the group consisting ANGPT2, TSP2, CRDL1, MATN2, GPVI, ESAM, C7, PLG, MMP-12, NPS-PLA2 and CdtA.
18. The composition of claim 1 , wherein the dissociation constant (K d ) for the ternary complex is at least 0.02 nM, or from about 0.01 nM to about 10 nM, or from about 0.02 nM to about 6 nM, or from about 0.02 nM to about 3 nM.